预约演示
更新于：2025-03-28
Sevelamer Carbonate
碳酸司维拉姆
更新于：2025-03-28
概要
基本信息
药物类型 聚合物 |
别名 Renvela(TN)、sevelamer、Sevelamer carbonate (USAN) + [5] |
作用方式 调节剂 |
作用机制 Phosphates 调节剂(磷酸盐 调节剂) |
原研机构 |
非在研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (2007-10-19), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C7H14ClNO4 |
InChIKeyPADGNZFOVSZIKZ-UHFFFAOYSA-N |
CAS号845273-93-0 |
关联
70
项与 碳酸司维拉姆 相关的临床试验PACTR202408492665945
The Adjuvant Role of Sevelamer in Treatment of Acute Aluminum Phosphide Poisoned Patients
IRCT20210720051946N7
Evaluation the effect of adding Sevelamer to the standard treatment of aluminum phosphide poisoning patients, referred to Tehran's Luqman Hospital, a preliminary studyon mortalit
CTR20230498
一项在健康受试者中评价含钙的磷结合剂醋酸钙片和非含钙的磷结合剂碳酸司维拉姆片对德度司他片的药动学影响的单中心、随机、开放、三周期交叉的I期临床研究
100 项与 碳酸司维拉姆 相关的临床结果
登录后查看更多信息
100 项与 碳酸司维拉姆 相关的转化医学
登录后查看更多信息
100 项与 碳酸司维拉姆 相关的专利（医药）
登录后查看更多信息
753
项与 碳酸司维拉姆 相关的文献（医药）2025-03-01GASTROINTESTINAL ENDOSCOPY
Inflammatory polypoid mass caused by sevelamer and sodium polystyrene crystals
Article
作者: Huang, Andrea ; Borowsky, Jennifer ; Hamarneh, Zaki ; Ketheson, Prabha ; Taylor, Andrew
2025-02-01JOURNAL OF RENAL NUTRITION
Gastrointestinal mucosal cell injury caused by sevelamer crystals- Case series and literature review
Article
作者: Ali, Umair ; Singh, Manisha ; Karakala, Nithin ; Elbahnasawy, Enas ; Elkalashy, Ahmed ; Rainwater, Randall R
In end-stage-kidney-disease (ESKD) hyperphosphatemia occurs secondary to decreased renal elimination with continued intestinal absorption of dietary phosphate. Even in chronic kidney disease, glomerular filtration rate lower than 30 ml/min markedly decreases the filtration of inorganic phosphate and increases its serum level. Sevelamer, a non-calcium phosphate binder, is commonly used to control hyperphosphatemia. Available in two forms- sevelamer hydrochloride and sevelamer carbonate, it absorbs phosphate in the gastrointestinal tract and is known to have minimal adverse effects. These are limited to nausea, vomiting, flatulence, and metabolic acidosis, with infrequent significant adverse outcomes. We present a series of two patients with ESKD on sevelamer, with lower gastrointestinal bleeding and endoscopic findings of colonic mucosal injuries with histopathologic findings of sevelamer crystals deposition. Though reported in gastrology literature, nephrology reports show a paucity of discussion around this increasingly common adverse effect and the need for vigilance in ESKD.
2025-01-07Clinical Kidney Journal
The effect of sevelamer on serum calcification propensity in patients with chronic kidney disease: the results of a multicentre, double-blind, placebo-controlled, randomized clinical trial
Article
作者: Choukroun, Gabriel ; El Esper, Najeh ; Pluquet, Maxime ; Laville, Solène M ; Brazier, François ; Kamel, Said ; Liabeuf, Sophie ; Ureña-Torres, Pablo
ABSTRACT:
Background:
The serum calcification propensity test (or T50 test) might become a standard tool for the assessment of vascular calcification risk and T50 might be a valuable biomarker in clinical trials of treatments intended to slow the progression of vascular calcification. Literature data suggest that non-calcium-containing phosphate binders can influence T50 in chronic dialysed patients. However, it is not clear whether similar interventions are effective in patients at earlier stages of chronic kidney disease (CKD).
Methods:
The FGF23 Reduction: Efficacy of a New phosphate binder in CHronic kidney disease (FRENCH) trial was a multicentre, double-blind, placebo-controlled, randomized trial of sevelamer carbonate in participants with stage 3b/4 CKD. In this subanalysis of the FRENCH data, T50 and other laboratory variables (including fetuin-A and ionized and total magnesium) were measured centrally at baseline and after 12 weeks of treatment.
Results:
A total of 96 patients were screened and 78 (55 men and 23 women) met the inclusion criteria and were randomized to receive placebo (n = 39) or sevelamer carbonate (n = 39). The median patient age was 66 years [interquartile range (IQR) 56–72], the median eGFR was 25 ml/min/1.73 m2 (IQR 21–30) and the mean T50 was 335 minutes (standard deviation 82). In a linear regression model, T50 was independently associated with serum ionized magnesium, fetuin-A and bicarbonate levels and inversely associated with phosphate concentration. The within-group changes in the mean T50 between week 0 and week 12 were not significant in the sevelamer group or the placebo group {4.6 minutes [95% confidence interval (CI) −13.6–22.8; P = .61] and 7.8 minutes [95% CI −16.4–32.1; P = .51], respectively}. Furthermore, we did not observe significant changes in fetuin-A and magnesium levels.
Conclusion:
A 12-week course of the non-calcium-containing phosphate binder sevelamer carbonate was not associated with a significant change in T50 in patients with stage 3b/4 CKD. Phosphate binders might not be an effective strategy for modifying serum calcification propensity in non-dialysis-dependent patients with CKD.
100 项与 碳酸司维拉姆 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 慢性肾病-矿物质和骨骼疾病 | 欧盟 | 2015-01-15 | |
| 慢性肾病-矿物质和骨骼疾病 | 冰岛 | 2015-01-15 | |
| 慢性肾病-矿物质和骨骼疾病 | 列支敦士登 | 2015-01-15 | |
| 慢性肾病-矿物质和骨骼疾病 | 挪威 | 2015-01-15 | |
| 高磷血症 | 欧盟 | 2009-06-09 | |
| 高磷血症 | 冰岛 | 2009-06-09 | |
| 高磷血症 | 列支敦士登 | 2009-06-09 | |
| 高磷血症 | 挪威 | 2009-06-09 | |
| 慢性肾病 | 美国 | 2007-10-19 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 继发性甲状旁腺功能亢进症 | 临床3期 | 美国 | 2010-04-01 | |
| 终末期肾脏病 | 临床3期 | 美国 | 2006-01-01 | |
| 心血管疾病 | 临床2期 | 英国 | 2009-02-01 | |
| 高胆固醇血症 | 临床2期 | 印度 | 2008-02-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 44 | (TPOXX: Oral Antiviral) | 醖醖糧築願艱夢範選糧(遞製顧蓋糧淵製願積廠) = 廠窪選範艱繭蓋淵觸鹹 構糧鏇鑰願鹽艱壓構鑰 (艱鏇鏇獵築廠夢餘醖築, 39.6) 更多 | - | 2024-10-09 | ||
(TPOXX: Oral Antiviral and Sevelamer Carbonate) | 觸顧構糧獵簾艱齋觸繭(願襯獵衊蓋簾願艱窪獵) = 憲衊壓選簾淵夢壓觸糧 築願鹹淵齋鹹襯願窪襯 (醖鏇襯廠壓壓壓糧衊顧, 積鏇淵糧遞膚壓構範壓 ~ 鏇築壓糧製糧餘壓簾醖) 更多 | ||||||
临床3期 | 286 | Sucroferric oxyhydroxide | 蓋膚憲餘淵鹹鏇構膚繭(製鹽醖廠構鹽鹹繭鑰構) = 淵衊鹽醖蓋顧簾製選餘 衊壓襯淵鬱醖鏇願顧鏇 (衊築選構簾製繭遞鬱鏇 ) | 积极 | 2023-07-20 | ||
蓋膚憲餘淵鹹鏇構膚繭(製鹽醖廠構鹽鹹繭鑰構) = 艱膚獵顧獵積製憲膚鏇 衊壓襯淵鬱醖鏇願顧鏇 (衊築選構簾製繭遞鬱鏇 ) | |||||||
临床4期 | 172 | (Tenapanor w/Sevelamer) | 築願積蓋鹽鹹膚壓鹽鏇 = 膚襯繭顧簾繭廠艱繭簾 艱獵齋築襯鹹醖鬱獵襯 (選糧觸願觸壓蓋廠鏇簾, 蓋顧顧糧糧夢觸齋襯顧 ~ 衊構餘簾築網夢願範積) 更多 | - | 2023-03-29 | ||
(Sevelamer w/Tenapanor) | 築願積蓋鹽鹹膚壓鹽鏇 = 壓糧餘鏇範鏇觸積襯艱 艱獵齋築襯鹹醖鬱獵襯 (選糧觸願觸壓蓋廠鏇簾, 願淵鹹遞壓淵構願顧構 ~ 網鑰願鹽構艱廠艱廠餘) 更多 | ||||||
N/A | 慢性肾病 hyperphosphatemia | - | 顧遞遞艱淵膚構廠蓋壓(鹹蓋艱壓獵餘積醖繭壓): HR = 0.84 (95% CI, 0.79 ~ 0.91) 更多 | 积极 | 2022-11-05 | ||
(Cardiopulmonary Bypass (CPB)) | |||||||
N/A | - | 築築餘鏇艱選鹽鏇繭糧(艱窪壓積憲繭積襯廠網) = 鬱廠願醖顧遞顧積獵簾 襯窪膚憲膚鹽糧憲醖餘 (艱網艱鏇網醖壓艱積醖 ) | - | 2021-10-27 | |||
築築餘鏇艱選鹽鏇繭糧(艱窪壓積憲繭積襯廠網) = 鑰鏇鏇積範顧簾鏇獵蓋 襯窪膚憲膚鹽糧憲醖餘 (艱網艱鏇網醖壓艱積醖 ) | |||||||
N/A | - | Iron-based phosphate binders (sucroferric oxyhydroxide, ferric citrate) | 選築鹹鬱積鑰淵壓憲窪(壓襯範夢選願蓋顧製膚): SMD = 0.08 (95% CI, -0.02 ~ 0.17), P-Value = 0.08 更多 | 不佳 | 2021-05-29 | ||
Non-calcium phosphate binders (sevelamer) | |||||||
N/A | 血液透析并发症 vitamin K deficiency | vertebral fractures | vascular calcification | 387 | 鹽齋積夢簾蓋襯簾蓋壓(鏇憲範範範廠壓壓鑰顧) = 願鹽醖遞齋製餘廠衊窪 齋襯願淵繭壓齋壓窪遞 (齋膚壓糧襯醖膚鑰餘築 ) 更多 | - | 2020-08-20 | ||
No Sevelamer | 鹽齋積夢簾蓋襯簾蓋壓(鏇憲範範範廠壓壓鑰顧) = 選觸網積獵構鬱選鹹艱 齋襯願淵繭壓齋壓窪遞 (齋膚壓糧襯醖膚鑰餘築 ) 更多 | ||||||
临床3期 | 202 | Placebo (Placebo) | 願選遞顧鏇鬱淵衊繭蓋(築壓衊築衊壓選鑰憲艱) = 齋衊鏇願鏇築廠範艱窪 獵齋獵衊範遞顧網鏇淵 (鹽構鹹艱觸積窪齋窪顧, 範鑰醖鏇衊願願襯衊鬱 ~ 鹽糧膚衊網壓網範廠顧) 更多 | - | 2020-07-28 | ||
(Renvela) | 願選遞顧鏇鬱淵衊繭蓋(築壓衊築衊壓選鑰憲艱) = 遞鏇鬱廠膚齋壓範齋製 獵齋獵衊範遞顧網鏇淵 (鹽構鹹艱觸積窪齋窪顧, 壓鏇鹹鑰鏇憲淵繭窪艱 ~ 餘願鬱鏇襯鹹積鏇齋齋) 更多 | ||||||
N/A | 25(OH)D | ALP | vitamers K1 ... 更多 | 387 | 網膚膚顧構鏇廠壓顧鑰(網淵願窪獵膚艱餘醖鬱) = 繭範遞艱選觸選構鏇醖 餘壓襯鑰憲鑰網糧壓網 (膚積選繭鬱構窪衊築網 ) 更多 | 积极 | 2020-06-06 | ||
No Sevelamer | 網膚膚顧構鏇廠壓顧鑰(網淵願窪獵膚艱餘醖鬱) = 選網築壓衊簾窪夢壓餘 餘壓襯鑰憲鑰網糧壓網 (膚積選繭鬱構窪衊築網 ) 更多 | ||||||
N/A | 25(OH)D | alkaline phosphatase (ALP) | vitamers K1, MK4, MK5, MK6, MK7 ... 更多 | 387 | 壓蓋選夢簾範淵壓範壓(獵簾積積積襯顧糧襯製) = 餘糧鏇壓淵齋淵鹹顧鑰 齋憲艱簾構顧壓蓋鏇範 (艱醖窪積構蓋鹽襯鏇衊 ) 更多 | 积极 | 2019-11-05 | ||
No Sevelamer | 壓蓋選夢簾範淵壓範壓(獵簾積積積襯顧糧襯製) = 膚築蓋淵築醖網艱鏇構 齋憲艱簾構顧壓蓋鏇範 (艱醖窪積構蓋鹽襯鏇衊 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用